Incannex Healthcare Inc
IXHL0.700USD
+0.614+720.63%
Handelsschluss 05/14, 16:00（ET）Kurse um 15 Minuten verzögert
12.45MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Incannex Healthcare Inc Unternehmen
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Unternehmensinformationen
Unternehmens-codeIXHL
Name des UnternehmensIncannex Healthcare Inc
IPO-datumMar 18, 2022
Gegründet am2023
CEOMr. Joel Latham
Anzahl der mitarbeiter9
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse8 Century Circuit
Stadt
BörseNASDAQ Global Market Consolidated
LandAustralia
Postleitzahl2153
Telefon61409840786
Website
Unternehmens-codeIXHL
IPO-datumMar 18, 2022
Gegründet am2023
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2022
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Australia
74.00K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: 6 hours ago
Update-Zeit: 6 hours ago
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Great Point Capital LLC
7.00%
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
4.51%
Valentine (Troy Robert)
3.15%
Other
71.33%
Aktionärsstatistik
Aktionäre
Anteil
Great Point Capital LLC
7.00%
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
4.51%
Valentine (Troy Robert)
3.15%
Other
71.33%
Art
Aktionäre
Anteil
Corporation
14.01%
Individual Investor
13.92%
Investment Advisor
8.28%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.07%
Other
63.36%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
36
9.08M
33.58%
+3.85M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
2022Q4
10
50.18K
0.08%
-3.79K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
7%
+1.93M
--
Mar 10, 2025
S.H.N. Financial Investments Ltd
1.93M
7%
+1.93M
--
Mar 10, 2025
Latham (Joel)
1.58M
5.73%
--
--
Oct 21, 2024
Valentine (Troy Robert)
1.04M
3.76%
--
--
Oct 21, 2024
Anastassov (George)
769.72K
2.79%
--
--
Oct 21, 2024
Changoer (Lekhram)
639.55K
2.32%
--
--
Oct 21, 2024
AdvisorShares Investments, LLC
165.50K
0.6%
+38.51K
+30.32%
Dec 31, 2024
Widdows (Peter)
270.85K
0.98%
--
--
Oct 21, 2024
Clark (Robert)
100.00K
0.36%
--
--
Oct 21, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
AdvisorShares Psychedelics ETF
2.41%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Anteil2.41%
Amplify Alternative Harvest ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten